Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.60 |
| ▸ | ADH1C | P00326 | 1/20 | 0.60 |
| ▸ | ADH1A | P07327 | 1/20 | 0.60 |
| ▸ | ADH7 | P40394 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL656733 | 0.81 | ADH1B (0.56) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL17092515 | 0.81 | ADH1B (0.56) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL29798082 | 0.79 | ADH1B (0.65) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL8713797 | 0.79 | ADH1B (0.65) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL25270311 | 0.75 | ADH1B (0.60) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL27354 | 0.75 | ADH1B (1.00) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL2117911 | 0.75 | ADH1B (0.60) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL5297466 | 0.75 | ADH1B (0.60) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL3084417 | 0.75 | ADH1B (0.60) | ADH1BADH1CADH1AADH7IDO1 | |
| SCHEMBL248336 | 0.75 | ADH1B (0.60) | ADH1BADH1CADH1AADH7IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4617401-A | ANTISPASMODIC AGENTS, VASODILATORS | SUNTORY LTD. (JP) | 1986-10-14 | — | — | US | claimed |
| EP-0039903-B1 | 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1986-04-09 | — | — | EP | claimed |
| EP-0039903-A2 | 8-Substituted pyrrolizidines and quaternary ammonium salts thereof | SUNTORY KABUSHIKI KAISHA (JP) | 1981-11-18 | — | — | EP | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | disclosed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | disclosed |
| US-20130174289-A1 | Na+/Mg2+ Exchanger | FBN - LEIBNITZ-INSTITUT FUR NUTZTIERBIOLOGIE (DE) | 2013-07-04 | — | — | US | disclosed |
| US-4617401-A | ANTISPASMODIC AGENTS, VASODILATORS | SUNTORY LTD. (JP) | 1986-10-14 | — | — | US | disclosed |
| EP-0039903-B1 | 8-SUBSTITUTED PYRROLIZIDINES AND QUATERNARY AMMONIUM SALTS THEREOF | SUNTORY KABUSHIKI KAISHA (JP) | 1986-04-09 | — | — | EP | disclosed |
| EP-0039903-A2 | 8-Substituted pyrrolizidines and quaternary ammonium salts thereof | SUNTORY KABUSHIKI KAISHA (JP) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | ADH1B 2288/4885ADH1C 1235/4885ADH1A 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.